Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Salix Pharmaceuticals Ltd Company Profile and SWOT Analysis

VIEWS: 32 PAGES: 32

This SWOT analysis and company profile is a crucial resource for industry executives and anyone looking to gain a better understanding of the company's business. ICD Research's "Salix Pharmaceuticals, Ltd.: Company Profile and SWOT Analysis" report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.

More Info
									Salix Pharmaceuticals, Ltd.

_________________________________________________________________________________



Salix Pharmaceuticals, Ltd.                                                       Financial Snapshot

                                                                                  Operating Performance
Fast Facts
                                       1700, Perimeter Park Drive, Morrisville,   The company reported revenues of US$336.97 million
Headquarters Address
                                       27560,United States of America             during 2010, with a CAGR of 12.75% during 2006–
                                                                                  2010. Its revenue grew at an annual rate of 44.69%
Telephone                              + 1 919 8621000
                                                                                  over the previous fiscal year. In 2010, the company
                                                                                  recorded an operating margin of -1.83%, as against -
Fax                                    + 1 919 8621095                            17.22% in 2009.

Website                                www.salix.com
                                                                                  Revenue and Margins
Ticker Symbol, Stock Exchange          SLXP, NASDAQ

Number of Employees                    390

Fiscal Year End                        December

Revenue (in US$ million)               336.97




SWOT Analysis

Strengths                              Weaknesses                                 Return on Equity

                                       Dependence on third party                  The company recorded a return on equity (ROE) of -
Increasing sales of Xifaxan
                                       manufacturers                              6.73% for 2010, as compared to its peers, Abbott
                                                                                  Laboratories (Ticker: ABT), GlaxoSmithKline plc
Strategic collaborations               Lawsuits                                   (Ticker: GSK) and Teva Pharmaceutical Industries
                                                                                  Limited (Ticker: TEVA), which recorded ROEs of
Strong top-line performance                                                       20.66%, 18.39% and 15.18% respectively. The
                                                                                  company reported an operating margin of -1.83% in
                                                                                  2010.
Opportunities                          Threats
Increasing healthcare expenditure in                                              Return on Equity
                                       Pricing of drugs
the US

New product developments               Product liability

                                       Tightening of the FDA‟s regulatory
Strategic agreement with Progenics
                                       oversight




                                                                                  Liquidity Position

                                                                                  The company reported a current ratio of 5.47 in 2010,
                                                                                  as compared to its peers, Abbott Laboratories,
                                                                                  GlaxoSmithKline plc and Teva Pharmaceutical
                                                                                  Industries Limited, which recorded current ratios of
                                                                                  1.29, 1.25 and 1.24 respectively. As of December
                                                                                  2010, the company recorded cash and short-term
                                                                                  investments of worth US$518.03 million, against
                                                                                  US$0.40 million current debt. The company reported
                                                                                  a debt to equity ratio of 0.80 in 2010 as compared to
                                                                                  its peers, Abbott Laboratories, GlaxoSmithKline plc
                                                                                  and Teva Pharmaceutical Industries Limited, which
                                                                                  recorded debt to equity ratios of 0.85, 1.70 and 0.25
                                                                                  respectively.




___________________________________________________________________________________________

Salix Pharmaceuticals, Ltd. - SWOT Profile                                                                               Page 1
Salix Pharmaceuticals, Ltd.

_________________________________________________________________________________


TABLE OF CONTENTS

1     Business Analysis ................................................................................................................................... 5
    1.1       Company Overview ................................................................................................................................................5
    1.2       Business Description ..............................................................................................................................................5
    1.3       Major Products and Services .................................................................................................................................6
    1.4       Key Financial Performance Indicators ...................................................................................................................7
      1.4.1       Revenue and Operating Profit ...........................................................................................................................7
      1.4.2       Asset, Liabilities and Capex ...............................................................................................................................8
      1.4.3       Operational Efficiency ........................................................................................................................................9
      1.4.4       Solvency ..........................................................................................................................................................10
    1.5       Competitive Benchmarking ..................................................................................................................................11
      1.5.1       Market Capitalization .......................................................................................................................................12
      1.5.2       Efficiency ..........................................................................................................................................................13
      1.5.3       Capital Expenditure ..........................................................................................................................................14
      1.5.4       Turnover – Inventory and Asset .......................................................................................................................15
      1.5.5       Liquidity .............................................................
								
To top